|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030685,
umls-concept:C0087111,
umls-concept:C0205164,
umls-concept:C0205460,
umls-concept:C0332281,
umls-concept:C0391871,
umls-concept:C0393022,
umls-concept:C0441471,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1456820,
umls-concept:C1963578
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-3-28
|
|
pubmed:abstractText |
In patients with low-grade non-Hodgkin's lymphoma, rituximab (MabThera) produces infusion-related toxicity, including fever, rigors, and chills in greater than 50% of those treated. The majority of these reactions are grade 1 or 2.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1466-4860
|
|
pubmed:author |
pubmed-author:AudhuyBB,
pubmed-author:BalterCC,
pubmed-author:BienvenuJJ,
pubmed-author:CasasnovasOO,
pubmed-author:ChristianBB,
pubmed-author:ChvetzoffRR,
pubmed-author:CoiffierBB,
pubmed-author:GabarroPP,
pubmed-author:Groupe d'Etude des Lymphomes de l'Adulte,
pubmed-author:HerbrechtRR,
pubmed-author:LederlinPP,
pubmed-author:MarisFF,
pubmed-author:MorelPP,
pubmed-author:SallesGG,
pubmed-author:SebbagDD,
pubmed-author:Solal-CelignyPP,
pubmed-author:TillyHH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
378-84
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11920277-Aged,
pubmed-meshheading:11920277-Aged, 80 and over,
pubmed-meshheading:11920277-Antibodies, Monoclonal,
pubmed-meshheading:11920277-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:11920277-Antineoplastic Agents,
pubmed-meshheading:11920277-B-Lymphocytes,
pubmed-meshheading:11920277-Blood Cell Count,
pubmed-meshheading:11920277-Complement Activation,
pubmed-meshheading:11920277-Complement C3a,
pubmed-meshheading:11920277-Humans,
pubmed-meshheading:11920277-Kinetics,
pubmed-meshheading:11920277-L-Lactate Dehydrogenase,
pubmed-meshheading:11920277-Lymphoma, B-Cell,
pubmed-meshheading:11920277-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:11920277-Middle Aged,
pubmed-meshheading:11920277-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.
|
|
pubmed:affiliation |
Laboratoire d'immunologie, CH Lyon-Sud, Pierre-Benite and Jeune Equipe 2267 from University Claude Bernard, Lyon, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
